ALLEGAN — Perrigo Co. (Nasdaq: PRGO) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg, a generic version of Mucinex 600mg tablets.
This launch consists of product packaged in bottles to a number of customers. The company said it expects to initiate its full-scale over-the-counter launch of product in blister packaging to its retail and wholesale customers in store brand or own label before the end of its current fiscal year.
Mucinex 600mg tablets (Guaifenesin Extended-Release Tablets, 600mg), an expectorant indicated to relieve chest congestion and make coughs more productive, has estimated annual sales of approximately $135 million.
“This is another great new product launch for our team and is representative of Perrigo’s unwavering commitment to make significant investments necessary to bring complex new products to market,” said Perrigo chairman and CEO Joseph C. Papa. “Perrigo continues to focus on making quality healthcare more affordable by expanding our customers’ offerings of high quality, value priced products.”
Perrigo develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The company’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. More at www.perrigo.com.